RxDoctor Payments Data

Lonnie Hammonds, MD

Dermatology · Mountain Home, ARNPI 1356464838

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Amgen at 25.6% of the total.

$4,296in general payments, 2019–2025

Across 224 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Johnson & Johnson$680
  • Lilly USA, LLC$516
  • Sun Pharmaceutical Industries Inc.$418
  • Sanofi$370
  • Regeneron Healthcare Solutions, Inc.$252
  • plus $962 from 14 others

What the payments were for

  • Food & beverage$4,02594%
  • Education$2706%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,296 in reported general payments places this provider in the 55th percentile of 75 dermatology providers in Arkansas.

See all dermatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$795,865
Medicare patients
2,073
Services billed
9,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast68$369,504
TremfyaGuselkumab19$266,992
OdomzoSonidegib Phosphate11$147,081
Dupixent PenDupilumab34$144,767
Humira(Cf) PenAdalimumab15$120,487
XolairOmalizumab29$80,040
Taltz AutoinjectorIxekizumab11$76,051
Fluorouracil130$9,044
Ketoconazole318$6,749
Triamcinolone Acetonide419$4,626
Betamethasone Dipropionate74$3,817
Clobetasol Propionate83$3,273
Metronidazole57$2,899
Clindamycin Phosphate80$2,878
Fluocinonide65$2,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,099$369,50468 claims
Johnson & JohnsonTremfya$680$266,99219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 75 dermatology providers in Arkansas.

Other dermatology in Mountain Home

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →